Evidence map›Paper›PMID 41135142›Full record

Trial reportSleep medicine2025

Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight.

Atul Malhotra, Ronald R Grunstein, Ali Azarbarzin, Scott A Sands, Xiangnan Dang, Sujatro Chakladar, Julia P Dunn, Beverly Falcon, Josef Bednarik

Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Sleep medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT05412004. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05412004 phase3completed

A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial

Ran2022Enrolled469Registered outcomes9Posted comparisons20ConditionsObesity, Obstructive Sleep ApneaArmsPlacebo, Tirzepatide
Open the trial in the graph
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Atul MalhotraUniversity of California San Diego, La Jolla, CA, USA.
Ronald R GrunsteinWoolcock Institute of Medical Research, Macquarie University and Royal Prince Alfred Hospital, Sydney, Australia.
Ali AzarbarzinBrigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Scott A SandsBrigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Xiangnan DangEli Lilly and Company, Indianapolis, IN, USA.
Sujatro ChakladarEli Lilly and Company, Indianapolis, IN, USA.
Julia P DunnEli Lilly and Company, Indianapolis, IN, USA.
Beverly FalconEli Lilly and Company, Indianapolis, IN, USA.
Josef BednarikEli Lilly and Company, Indianapolis, IN, USA. Electronic address: jbednari@amgen.com.

Funding

The cardiovascular consequences of sleep apnea plus COPD (Overlap syndrome)R01HL166485 · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2025 to 2025
$776k
Developing a Diverse Next Generation of Leaders in Respiratory ScienceT32HL166127 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2023 to 2025
$761k
VentNet: A Real-Time Multimodal Data Integration Model for Prediction of Respiratory Failure in Patients with COVID-19R01HL157985 · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2025 to 2025
$724k
Sleep Apnea Endophenotypes: One Size Does Not Fit AllR01HL154926 · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2025 to 2025
$663k
NHLBI NIH HHS R01 HL148436NHLBI NIH HHS R01 HL154926NHLBI NIH HHS R01 HL157985NHLBI NIH HHS R01 HL166485NHLBI NIH HHS T32 HL166127NIA NIH HHS R01 AG063925
6 · The paper itself

Abstract

backgroundObstructive sleep apnea (OSA) is a common disorder with major cardiometabolic and neurocognitive sequelae. It affects up to 1 billion people globally and is frequently attributable to excess weight [1]. Tirzepatide is a once-weekly, dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is FDA-approved for the treatment of moderate-to-severe OSA in adults with obesity.

methodsThe SURMOUNT-OSA program included two 52-week, randomized, double-blind, placebo-controlled, Phase 3 studies (Study 1 and Study 2). The objective of these analyses was to assess time to treatment effects for improvements in apnea-hypopnea index (AHI) and sleep apnea-specific hypoxic burden (SASHB), and how these changes correspond with body weight reduction. We also aimed to investigate weight-dependent and weight-independent effects of tirzepatide treatment for OSA using linear regression analysis.

resultsThe results of peripheral AHI (pAHI) and SASHB measurements from WatchPAT 300 in Study 1 were consistent with the polysomnographic (PSG) findings. The tirzepatide-associated improvements in pAHI were significant vs baseline as early as Week 4. However, the estimated treatment difference compared to placebo was not significant until Week 20 for both pAHI and WatchPAT-based SASHB. The magnitude of changes in AHI and SASHB were associated with achieved weight reduction in both studies.

conclusionsThe results from these post hoc analyses provide details regarding the time course of resolution and insights regarding the impact of weight reduction on OSA improvements. Additional research is needed to determine the impact of body weight reduction versus other effects of tirzepatide on the improvements in OSA measures. SURMOUNT-OSA ClinicalTrials.gov number NCT05412004.

Indexed as

Body WeightGastric Inhibitory PolypeptideSleep Apnea, ObstructiveSleep Apnea SyndromesAdultDouble-Blind MethodFemaleHumansMaleMiddle AgedObesityPolysomnographyTirzepatideTreatment OutcomeGastric Inhibitory PolypeptideTirzepatideApnea-hypopnea indexObstructive sleep apneaSleep apnea-specific hypoxic burdenSURMOUNT-OSA

Identifiers

PMID41135142
PMCPMC12723708

What Socratic holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.